

28 September, 2020

The Journal of Medical Virology has peer reviewed, approved and published the results of Enzymatica's *in vitro* study on SARS-CoV-2

On July 20 Enzymatica announced the preliminary results from the *in vitro* study, showing that the mouth spray ColdZyme® deactivates SARS-CoV-2, the virus causing the COVID-19 pandemic. The results of the study, which also includes the common cold virus HCoV-229E, have now been published in the Journal of Medical Virology in the article "Inactivation of SARS-CoV-2 and HCoV-229E *in vitro* by a medical device mouth spray".

The conclusion of the study is that the mouth spray ColdZyme can inactivate the respiratory coronaviruses SARS-CoV-2 and HCoV-229E *in vitro*, by 98.3% and 99.9% respectively. Although the *in vitro* results presented cannot be directly translated into clinical efficacy, the study indicates that ColdZyme might offer a protective barrier against SARS-CoV-2 and a decreased risk of COVID-19 transmission.

<https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.26554>

FOR MORE INFORMATION, PLEASE CONTACT:

Claus Egstrand, Chief Operating Officer Enzymatica AB
Phone: +44 7780 22 8385 | E-mail: claus.egstrand@enzymatica.com

Carl-Johan Wachtmeister, Communication manager Enzymatica AB
Phone: +46 (0)701-88 50 21 | Email: carl-johan.wachtmeister@enzymatica.com

ABOUT ENZYMATICA AB

Enzymatica AB is a Swedish life science company that develops and sells health care products for primarily conditions of the ear-nose-and-throat region. The products are based on a barrier technology that includes marine enzymes. The company's first product is the medical device ColdZyme®, a mouth spray against common cold. The product has been launched in 15 countries on 3 continents. The strategy is to continue to grow by developing more health care products and strengthening the company's position in existing markets and expanding into new geographic markets through established partners. The company has its headquarters in Lund and is listed on Nasdaq First North Growth Market. For more information, visit: www.enzymatica.com and www.enzymatica.se/en/section/media/press-releases

Enzymatica's certified adviser is Erik Penser Bank. Phone: +46 (0)8 463 83 00. Email: certifiedadviser@penser.se

Enzymatica AB (publ)

Ideon Science Park, SE-223 70 Lund, Sweden
Tel: +46 (0)46-286 31 00, Web: enzymatica.se